Drug Pricing
The Trump administration and state governments are taking action on drug pricing. Keep up with our comprehensive coverage of administrative and legislative activity and what it means for industry, plans, providers, and patients.
Featured Content
Recent Proposals by the Administration Hint at Areas of Focus for Upcoming Drug Pricing Plan
President Trump is expected to announce a drug pricing plan in the coming weeks; signals from the White House indicate potential alignment around several priority policies.
The Seven Types of Drug Pricing Legislation to Watch
Increasingly, states are taking steps to control prescription drug spending and prices.
Payer Trends in Oncology
The shift from volume to value has played a significant role in shaping current payer behavior in the oncology space.
Webinar: Drug Pricing: Where’s the Future Headed?
Avalere experts review proposed drug pricing policies from each stakeholder's perspective across the industry and the implications each might carry.
Industry Funding Spurs FDA’s Review Activities for Prescription and Generic Drugs
User fees are increasingly central to the funding of the drug and device review programs, and in some cases these fees account for a larger proportion of the Food and Drug Administration's (FDA) budget than congressionally-appropriated monies. For example, user fees account for 68 percent of the FDA's review budget for prescription drugs, while 58 percent of the review budget for generic drugs comes from user fees.
